Role of extended release quetiapine in the management of bipolar disorders

23Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Atypical antipsychotics have become a widely utilized component of the bipolar disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed atypicals. Over the last decade all atypical drugs except for clozapine have received a Food and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder and acute manic or mixed episodes in bipolar I disorder based on two placebo-control trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR formulation is intended for once-daily administration. This drug profile of quetiapine XR will address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability and clinical trials in bipolar disorder. © 2010 Al Jurdi et al, publisher and licensee Dove Medical Press Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Al Jurdi, R. K., Dixit, L. A., & Sajatovic, M. (2010). Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatric Disease and Treatment. Dove Medical Press Ltd. https://doi.org/10.2147/ndt.s4903

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free